This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

CSL - CSL Limited

Jump to new
earnings up, dividend up, a few questions over Vifor. In a slowing economy, some investors will gain succour the pathway is discernable and some will fret that future growth could be clipped.

CSL said that on the same basis, 2023-24 underlying profit was up by 15% to US$3.01 billion. And looking to the coming year, the company said it expects underlying profit of between US$3.2 billion and US$3.3 billion at constant currency in 2024-25, which would be a rise of between 10% and 13%. That will be on slower revenue growth, with CSL estimating it will grow by “approximately 5-7% over FY24 at constant currency”. And that appears to be what investors didn’t like.

CSL has been saying for a while now that it expects annualised double-digit earnings growth over the medium term.
 
Easier with double digit inflation as well so quite doable imho
 
Didn't drop for long, now over $303.
Personally, as a long term shareholder since the float I know they under promise.
When they give advance estimates, I assume its based on worst case.
 
Knobby22 said:
Didn't drop for long, now over $303.
Personally, as a long term shareholder since the float I know they under promise.
When they give advance estimates, I assume its based on worst case.
Click to expand...

As with most in this sector, many investors focus on the immediate. Do you know what CSL's R&D spend is by any chance?
 
We had a debate about csl PE
And lack of return via dividends in my view
If we agree that we can get a td at 5 %
And sp is 303 aud today.easy number
Div is the past but let's suppose it carries on
Dividend being 1.5%
In the next 12 month csl would underscore by 3.5% or roughly $10$ per share
I put a calendar reminder
If csl is above 313 post dividends in a year, csl beat a td, otherwise you should have sold today , put your money in a td and then buy again in 12 months if you want to
Note that a td at 5% with current inflation is pathetic but let's do a simple test.
Calendar entry done
 
Bellcose said:
As with most in this sector, many investors focus on the immediate. Do you know what CSL's R&D spend is by any chance?
Click to expand...
$1.4 billion. 2500+ employees in 10 locations.

CSL’s R&D pipeline
CSL’s strong R&D pipeline includes potential new treatments that use these platforms in alignment with its leading-edge scientific expertise and commercial capabilities across CSL’s six therapeutic areas: immunology; haematology; cardiovascular and metabolic; respiratory; nephrology and transplant; and vaccines.

In 2023/24 CSL invested US$1.4 billion in R&D for its three businesses. Looking towards 2030, R&D continues to strive to deliver on the current portfolio of prospective medicines and vaccines and build a comprehensive and innovative pipeline with the potential to meaningfully impact the lives of patients and to public health.
 
I didn't know CSL was into term deposits. I must investigate further. this site has such a wealth of contextual information
 
dyna said:
They're brilliant if your marginal tax rate ain't like mine .
( 47 % ) So , lose half of the interest rate to Treasury plus inflation gone with the wind at end of the term .
Click to expand...
sure but still better than net capital loss
 
CSL has recovered most of the drop seen on 13 August when results came out. Now $307.50

the last 3-4 months has seen the shares rally ahead of the index (of which it is a not insignificant contributor)
.
 
Dona Ferentes said:
CSL has recovered most of the drop seen on 13 August when results came out. Now $307.50

the last 3-4 months has seen the shares rally ahead of the index (of which it is a not insignificant contributor)
.
View attachment 182792
Click to expand...
$309.75 as I speak.
I read an article recently about overly reactive investors doing more poorly than your typical investor. This CSL thread and that short share market dip are a great example of where this is true. The computerised traders are too fast.
 
one view .. James Gruber

CSL: a big boat proving harder to move​

After IPO’ing at $2.40 in 1994, CSL (ASX: CSL) has been a wonderful Australian success story. It’s one of the few Australian companies that’s become a global leader in its field. And shareholders have benefited mightily, with the stock price up a cool 126x over the past 30 years (excluding dividends)*.


Source: Morningstar

With a market capitalization of $148 billion, though, size is becoming more of an issue. Growth is proving more difficult to come by, and acquisitions harder to find. This is best illustrated by the following chart.



The chart shows that returns of capital have plummeted since 2015. In that year, CSL acquired the flu vaccine business of Novartis. Despite the success of this business, returns have declined. That trend has accelerated following the 2022 purchase of Vifor.

This doesn’t rule out that returns may improve from here, but I’d suggest that the glory days of CSL are behind it, and tougher times may lay ahead.

(* actually higher than that, given a share split )
 
It is not good for shareholders but good for the company, not a bad thing to be too big to grow much more/faster
 
You must log in or register to reply here.

Similar threads

Can you make money investing in watches?
2
Replies
26
Views
908
Knobby22
GMIN - G Mining Ventures Corp. (TSX)
Replies
1
Views
399
mullokintyre
18.6 Year Property/Sharemarket Cycle …
Replies
2
Views
955
Rosscoe62
GME - GameStop Corp (NYSE)
2
Replies
20
Views
3K
GamestopVALUE
The role of Private Equity
Replies
5
Views
2K
Dona Ferentes
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...